Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9983523 | 0.90 | BACE1 (0.41) | BACE1NT5ECYP2C19 | |
| SCHEMBL2223359 | 0.82 | — | — | |
| SCHEMBL14914729 | 0.82 | KDM4E (0.46) | BACE1CYP3A4 | |
| SCHEMBL10220222 | 0.77 | BACE1 (0.53) | BACE1NT5ECYP3A4CYP2C9CYP2C19 | |
| SCHEMBL28027280 | 0.77 | BACE1 (0.42) | BACE1NT5ECYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2556988 | 0.74 | BACE1 (0.50) | BACE1NT5ECYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2003231 | 0.73 | BACE1 (0.57) | BACE1NT5ECYP3A4CYP2C9CYP2C19 | |
| SCHEMBL508438 | 0.73 | GBA1 (0.33) | — | |
| SCHEMBL263494 | 0.72 | BACE1 (0.47) | BACE1NT5ECYP3A4CYP2C9CYP2C19 | |
| SCHEMBL264392 | 0.71 | BACE1 (0.46) | BACE1NT5ECYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993767-B2 | Multiphoton activable quinoline derivatives, their preparation and their uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-03-31 | — | — | US | disclosed |
| EP-2523937-B1 | Multiphoton activable quinoline derivatives, their preparation and their uses | CENTRE NAT RECH SCIENT (FR) | 2015-03-11 | — | — | EP | disclosed |
| US-20130116281-A1 | Multiphoton Activable Quinoline Derivatives, Their Preparation and Their Uses | UNIVERSITÉ PARIS CITÉ (FR) | 2013-05-09 | — | — | US | disclosed |
| EP-2523937-A1 | MULTIPHOTON ACTIVABLE QUINOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USES | Centre National De La Recherche Scientifique (FR) | 2012-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116281-A1 | Multiphoton Activable Quinoline Derivatives, Their Preparation and Their Uses | NQO2, ACHE, NQO1 | BACE1 1792/4885NT5E 146/4885CYP3A4 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.